BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study - Concepedia

Concepedia

Publication | Open Access

BL‐8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open‐label safety and efficacy phase 2a study

DOI Full Paper Access

37

Citations

22

References

2020

Year

Gautam Borthakur, Yishai Ofran, Martin S. Tallman, James M. Foran, Geoffrey L. Uy, John F. DiPersio, Margaret M. Showel, Avichai Shimoni, Arnon Nagler, Jacob M. Rowe,

Abstract

The current results demonstrate the efficacy of CXCR4 targeting with BL-8040 and support continued clinical development in acute myelogenous leukemia.

References

	Year	Citations

Page 1